N/A
N=35
Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema
Breast Cancer · Head and Neck Cancer · Lymphedema
Bottom Line
View on ClinicalTrials.gov: NCT00828516 ↗Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Jan 2013
Primary outcome: Primary: Change From Baseline in Patient-specified and Reported Symptoms on the Measure Yourself Medical Outcome Profile (MYMOP) — 1.51 units on a scale — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Acupuncture and moxibustion (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- East and North Hertfordshire NHS Trust
- Primary completion
- Sep 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Patient-specified and Reported Symptoms on the Measure Yourself Medical Outcome Profile (MYMOP) |
1.51 | <0.001 sig |
| PRIMARY Change From Baseline in Patient-specified and Reported Symptoms on the Measure Yourself Medical Outcome Profile |
1.32 | <0.001 sig |
Summary
RATIONALE: Acupuncture and moxibustion may improve well-being and quality of life in patients with lymphedema caused by breast cancer or head, neck, and throat cancer.
PURPOSE: This clinical trial is studying how well acupuncture given together with moxibustion works in improving well-being and quality of life in patients with breast cancer or head, neck, and throat cancer who are undergoing standard treatment for lymphedema.
Eligibility Criteria
INCLUSION CRITERIA
- male or female patients with either breast or head and neck cancer
- diagnosis of mild to moderate uncomplicated lymphoedema
- age 18 or over
- under the care of the lymphoedema service for at leas:
- two months (head and neck cancer patients)
- three months (breast cancer patients)
- no active cancer disease
- at least 3 months since prior active cancer treatment (surgery, radiotherapy, chemotherapy, intravenous treatment)
- more than 6 months since prior acupuncture treatment
- concurrent adjuvant hormonal therapy allowed
- concurrent anti-depressant medication allowed provided there has been no change in prescription or dosing within the past 3 months and patient intends to remain on the medication for the duration of study treatment and follow-up
- Able to understand and communicate in English
- Able to travel to the Lynda Jackson Macmillan Centre for treatment
- Able to attend treatment once weekly for at least 7 consecutive weeks
- Able to complete outcome measures
EXCLUSION CRITERIA
- bilateral breast cancer
- advanced cancer disease
Data sourced from ClinicalTrials.gov (NCT00828516). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.